Among the 11 potential repurposed drugs, 9 were enriched in the NSCLC pathway (hsa05223) (Figure 6A) and 11 were enriched in the “Proteoglycans in cancer (hsa05205)”, “VEGF signaling pathway (hsa04370)”, etc. pathways involved in the development of cancer (Figure 6B). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.